Merck & Co., Inc. (MRK)

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Ticker
MRK
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$356.53B
52-week range
$91.49 - $156.92

Valuation

Share price
$144.46 (close of Nov 16, 2026)
P/E (TTM)
144.46x
Price to book
7.93x
Price to free cash flow
24.18x
Enterprise value
$400.75B
Book value per share
$18.21

Price performance

PeriodChange
1 day-2.23%
5 days-2.89%
1 month-1.02%
3 months+6.35%
6 months+29.70%
Year to date+37.24%
1 year+55.47%
3 years+41.64%
5 years+71.75%
10 years+141.73%
All time+9,698.09%

Short interest

As of
Oct 30, 2026
Short % of float
1.08%
Shares short
26.60M
Days to cover
2.36
Change since prior report
-0.82%
Source
FINRA consolidated short interest

Members of Congress who disclosed MRK trades

Gilbert Ray Cisneros · Julie Johnson · Maria Elvira Salazar · Marjorie Taylor Greene · Robert Bresnahan · Bruce Westerman · Byron Donalds · Jared Moskowitz · Jefferson Shreve · Josh Gottheimer · Lisa McClain · Ritchie Torres

And 5 others

Super investors holding MRK

Bill Nygren (Harris Associates LP) · Ken Griffin (Citadel) · Sarah Ketterer (Causeway Capital Management LLC) · Kahn Brothers (Kahn Brothers Group) · Prem Watsa (Fairfax Financial Holdings) · Dodge & Cox (Dodge & Cox Funds) · Mairs & Power (Mairs & Power Inc) · Christopher Bloomstran (Semper Augustus Investments Group LLC) · Ray Dalio (Bridgewater Associates) · Richard Pzena (Pzena Investment Management) · David Katz (Matrix Asset Advisors Inc) · Thomas Russo (Gardner Russo & Quinn LLC)

Profitability and growth

Return on equity
34.66%
Return on invested capital
19.24%*
Return on assets
13.34%
Return on capital employed
20.66%*
Gross margin
74.80%
Net margin
28.08%
EBITDA margin
43.47%
Revenue growth
1.31%
Net income growth
6.64%
Free cash flow growth
-31.70%

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash flow and balance sheet

Free cash flow yield (TTM)
4.14%
Current ratio
1.35x
Net debt to EBITDA
3.14x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$65.01B
Cost of revenue
$16.38B
Gross profit
$48.63B
EBITDA
$28.26B
Net income
$18.25B
Earnings per share
$7.30
Research and development
$15.79B
Interest expense
$1.36B
Shares outstanding
2.50B

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$65.01B$48.63B$18.25B$7.30
2024-12-31$64.17B$48.98B$17.12B$6.76
2023-12-31$60.12B$43.99B$365.00M$0.14
2022-12-31$59.28B$41.87B$14.52B$5.73
2021-12-31$48.70B$35.08B$13.05B$5.16
2020-12-31$41.52B$27.90B$7.07B$2.79
2019-12-31$39.12B$27.11B$9.84B$3.84
2018-12-31$42.29B$28.79B$6.22B$2.34
2017-12-31$40.12B$27.21B$2.39B$0.88
2016-12-31$39.81B$25.78B$3.92B$1.42

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3174.80%28.08%34.66%19.24%*
2024-12-3176.32%26.68%36.91%22.05%*
2023-12-3173.17%0.61%0.97%2.10%*
2022-12-3170.63%24.49%31.52%20.18%*
2021-12-3172.02%26.79%34.11%18.06%*
2020-12-3167.20%17.02%27.82%9.10%*
2019-12-3169.29%25.16%37.86%12.18%*
2018-12-3168.06%14.71%23.14%13.40%*
2017-12-3167.82%5.97%6.93%6.17%*
2016-12-3164.75%9.85%9.73%7.11%*

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash and debt by year

Period endCashDebt
2025-12-31$14.56B$46.75B
2024-12-31$13.24B$34.46B
2023-12-31$6.84B$33.68B
2022-12-31$13.19B$28.75B
2021-12-31$8.10B$30.69B
2020-12-31$8.05B$25.36B
2019-12-31$10.43B$22.74B
2018-12-31$8.86B$19.81B
2017-12-31$8.49B$21.35B
2016-12-31$14.31B$24.27B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$12.36B$820.00M
2024-12-31$18.10B$761.00M
2023-12-31$9.14B$645.00M
2022-12-31$14.71B$541.00M
2021-12-31$8.67B$479.00M
2020-12-31$5.82B$441.00M
2019-12-31$10.07B$388.00M
2018-12-31$8.31B$348.00M
2017-12-31$4.56B$312.00M
2016-12-31$8.76B$300.00M

Dividend history

Most recent payment
Sep 15, 2026
Paid in the last twelve months
$3.40
Payment dateDividend per share
2026-09-15$0.85
2026-06-15$0.85
2026-03-16$0.85
2025-12-15$0.85
2025-09-15$0.81
2025-06-16$0.81
2025-03-17$0.81
2024-12-16$0.81

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-29Sep 2026$2.12
2026-08-04Jun 2026-$0.26
2026-04-30Mar 2026-$1.51
2026-02-03Dec 2025$2.03
2025-10-30Sep 2025$2.36
2025-07-29Jun 2025$2.01
2025-04-24Mar 2025$2.15
2025-02-04Dec 2024$1.69

Filings and sources

Company website
merck.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Novartis AG (NVS) · AbbVie Inc. (ABBV) · AstraZeneca plc (AZN) · Johnson & Johnson (JNJ) · Amgen Inc (AMGN) · Eli Lilly & Co (LLY) · Gilead Sciences, Inc. (GILD) · Pfizer Inc (PFE)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades